Today, on behalf of the National Forum, Executive Director John Clymer presented comments to the Centers for Medicare and Medicaid Services Listening Session on Medicare Drug Price Negotiation for Eliquis. Clymer urged CMS to ensure the Medicare Drug Price Negotiation Program:
• supports evidence-based strategies for appropriate care, and protects beneficiary access;
• guards against potential unintended consequences, such as utilization management that could result in reduced access to appropriate treatment; and
• aligns incentives for all stakeholders.
